PREX2 (phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2) is a homolog of PREX1, and belongs to the Dbl (Diffuse B-cell lymphoma) family guanine nucleotide exchange factors (GEFs) family. It contains a PH (pleckstrin homology) domain, which is essential for substrate recognition. It also contains DH (Dbl-homology) domain and PDZ domains. This protein has a molecular weight of 183kDa.
Synonyms: Anti-DEP.2; Anti-DEPDC2; Anti-FLJ12987; Anti-P-REX2; Anti-PPP1R129
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: PREX2 (phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2) interacts with and suppresses PTEN (phosphatase and tensin homolog) protein in breast cancer. Mutations in this gene are linked to human melanomas, and abnormal expression of this gene leads to tumorigenesis in immortal melanocytes. Mutations in this gene are also associated with lung, colon and pancreatic cancer. Thus, mutations are thought to turn PREX2 in an oncogene. It recognizes and interacts with Rac-1 protein, RhoA and Cdc42, and activates them. This, in turn, is activated by PI-3K (Phosphoinositide 3-kinase). It is induced by CXCL9 (Chemokine (C-X-C Motif) Ligand 9), which results in enhanced invasiveness of hepatocellular carcinoma. PREX2 is also up-regulated in gastric cancer (GC), and this expression is suppressed by miR-338-3p, which acts as a tumor suppressor in GC.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC